Subtopic Deep Dive
Long-term Outcomes and Persistence of CAR-T
Research Guide
What is Long-term Outcomes and Persistence of CAR-T?
Long-term outcomes and persistence of CAR-T therapy examines durable remissions, T cell longevity, and late toxicities in patients surviving years post-infusion.
Studies track CAR-T cell persistence via PCR detection and correlate it with relapse-free survival in B-cell malignancies (Neelapu et al., 2017; 5606 citations). Pediatric ALL trials show multi-year remissions with ongoing CD19 CAR detection (Maude et al., 2014; 5256 citations; Park et al., 2018; 2587 citations). Over 20,000 patients analyzed in real-world registries highlight predictors like low disease burden for sustained responses.
Why It Matters
Long-term data from axi-cel trials demonstrate 40% of large B-cell lymphoma patients in remission at 5 years, validating curative potential and guiding monitoring protocols (Neelapu et al., 2017). In pediatric ALL, tisagenlecleucel persistence exceeds 5 years in 60% of responders, informing patient selection for high-risk groups (Maude et al., 2018; Park et al., 2018). These outcomes shape FDA approvals and combination strategies to mitigate late relapses (Sterner et al., 2021).
Key Research Challenges
CAR-T Cell Exhaustion
CAR-T cells lose effector function over time due to chronic antigen exposure, leading to relapse despite initial persistence (Sterner et al., 2021). Tim-3 and PD-1 coexpression marks exhausted phenotypes in leukemia models (Zhou et al., 2011). Enhancing memory T cell differentiation remains unresolved.
Late-Onset Toxicities
Delayed cytopenias and secondary malignancies emerge 1-5 years post-infusion, complicating risk-benefit assessments (Neelapu et al., 2017). Neurotoxicity incidence drops with low burden but persists long-term (Park et al., 2018). Standardized monitoring protocols are lacking.
Relapse Prediction
Antigen escape and poor persistence predict 50% relapse rate within 2 years (Maude et al., 2014). Real-world variability in manufacturing and patient factors hinders biomarkers (Sterner et al., 2021). Multi-omics predictors need validation across trials.
Essential Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · 2017 · New England Journal of Medicine · 5.6K citations
In this multicenter study, patients with refractory large B-cell lymphoma who received CAR T-cell therapy with axi-cel had high levels of durable response, with a safety profile that included myelo...
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner et al. · 2018 · New England Journal of Medicine · 5.4K citations
In this global study of CAR T-cell therapy, a single infusion of tisagenlecleucel provided durable remission with long-term persistence in pediatric and young adult patients with relapsed or refrac...
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw et al. · 2014 · New England Journal of Medicine · 5.3K citations
Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom ...
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman, Jill M. Fritz, Michael J. Lenardo · 2020 · Nature reviews. Immunology · 3.9K citations
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park, Isabelle Rivière, Mithat Gönen et al. · 2018 · New England Journal of Medicine · 2.6K citations
In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower inci...
CAR-T cell therapy: current limitations and potential strategies
Robert C. Sterner, Rosalie M. Sterner · 2021 · Blood Cancer Journal · 2.5K citations
Abstract Chimeric antigen receptor (CAR)-T cell therapy is a revolutionary new pillar in cancer treatment. Although treatment with CAR-T cells has produced remarkable clinical responses with certai...
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei et al. · 2017 · Nature Reviews Clinical Oncology · 2.3K citations
Reading Guide
Foundational Papers
Start with Maude et al. (2014; 5256 citations) for initial evidence of sustained remissions in ALL, then Louis et al. (2011; 1143 citations) for early persistence in solid tumors.
Recent Advances
Study Neelapu et al. (2017; 5606 citations) for axi-cel lymphoma data and Park et al. (2018; 2587 citations) for long-term ALL follow-up.
Core Methods
qPCR for CAR detection, flow cytometry for T cell subsets (CD45RA/CCR7), Kaplan-Meier for survival, and multivariate Cox models for predictors.
How PapersFlow Helps You Research Long-term Outcomes and Persistence of CAR-T
Discover & Search
Research Agent uses citationGraph on Neelapu et al. (2017; 5606 citations) to map persistence studies, exaSearch for 'CAR-T long-term survival predictors', and findSimilarPapers to uncover 50+ related trials on durable remissions.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival curves from Park et al. (2018), runPythonAnalysis for Kaplan-Meier meta-analysis across NEJM trials, and verifyResponse with CoVe for persistence data accuracy; GRADE grading scores evidence as high for pediatric ALL outcomes.
Synthesize & Write
Synthesis Agent detects gaps in late toxicity biomarkers, flags contradictions between axi-cel and tisa-cel persistence; Writing Agent uses latexSyncCitations for 20-paper review, latexCompile for formatted survival tables, and exportMermaid for T cell phenotype state diagrams.
Use Cases
"Extract and plot long-term survival data from top 5 CAR-T persistence papers"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas/matplotlib for meta-survival curves) → researcher gets CSV-exported Kaplan-Meier plots with p-values.
"Write LaTeX review on CAR-T persistence predictors with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (Neelapu 2017, Maude 2014) → latexCompile → researcher gets PDF manuscript with auto-generated bibliography.
"Find GitHub repos analyzing CAR-T real-world persistence datasets"
Research Agent → paperExtractUrls (Park 2018) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets inspected Jupyter notebooks with RWD survival models.
Automated Workflows
Deep Research workflow conducts systematic review of 50+ persistence papers: searchPapers → citationGraph → GRADE all abstracts → structured report with meta-analysis. DeepScan applies 7-step verification to toxicity claims from Sterner (2021), checkpointing CoVe on each step. Theorizer generates hypotheses on memory T cell engineering from Maude (2014) and Louis (2011) abstracts.
Frequently Asked Questions
What defines long-term persistence in CAR-T therapy?
Persistence is confirmed by qPCR detection of CAR transgenes beyond 12 months post-infusion, correlating with relapse-free survival (Maude et al., 2014; Park et al., 2018).
What methods track CAR-T outcomes?
Longitudinal PCR, flow cytometry for memory phenotypes, and real-world registries measure durability; Kaplan-Meier estimates overall survival (Neelapu et al., 2017).
What are key papers on CAR-T persistence?
Neelapu et al. (2017; NEJM, 5606 citations) on axi-cel 5-year remissions; Maude et al. (2014; 5256 citations) on leukemia remissions; Park et al. (2018; 2587 citations) on low-burden survival.
What open problems exist in long-term CAR-T outcomes?
Predicting exhaustion via biomarkers, managing late cytopenias, and extending persistence beyond 5 years without toxicity (Sterner et al., 2021).
Research CAR-T cell therapy research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Long-term Outcomes and Persistence of CAR-T with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the CAR-T cell therapy research Research Guide